NCT02602704CompletedPhase 4
Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Hanyang University
- Enrollment
- 114
- Locations
- 1
- Primary Endpoint
- Change of Bone Mineral Density (BMD)
Study Overview
Brief Summary
- The purpose of this study is to study the effectiveness of bazedoxifene in preventing loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.
- This is a randomized, controlled, open-label extension study for 48 or 56 weeks. At study entry, all patients will receive elemental calcium (1200 mg daily) and vitamin D (800 IU daily) and will be randomized by blocks of two to receive either bazedoxifene (20 mg/day) or none.
Detailed Description
- The purpose of this study is to study the effectiveness of bazedoxifene in preventing loss of bone mineral density (BMD) and trabecular bone score (TBS), and any fractures in postmenopausal rheumatoid arthritis (RA) patients receiving long-term GCs.
- This was a randomized, controlled, open-label study conducted for 56 weeks. Four trial visits occurred over the course of the 56 weeks. At study entry, all patients who took elemental calcium (1200 mg daily) and vitamin D (800 IU daily) were assigned by blocks of two to receive either bazedoxifene (20 mg/day) (bazedoxifene group) or not (control group).
- Randomization was performed by an independent coordinator. Participants were followed-up at 24 weeks and 48 weeks with special attention to RA flares and occurrence of AEs.
- Demographic characteristics such as age, sex, and medications related to RA, as well as laboratory result such as complete blood count (CBC), chemistry, and levels of inflammatory markers were collected at enrollment. BMD and trabecular bone score (TBS) were assessed at 0 and 48 weeks, and levels of bone turnover markers were assessed at 0, 24, and 48 weeks. At 56 weeks, the occurrence of AEs was assessed.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 45 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Female RA patients ≥ 45 years old with self-reported postmenopausal for ≥12 months or prior hysterectomy with bilateral oophorectomy. Female patients ≥ 55 years old who had prior hysterectomy without oophorectomy or with unilateral oophorectomy.
- •Having been receiving low to moderate dose of glucocorticoids (prednisone ≤7.5 mg/day or equivalent) for ≥3 months prior to entry. (When taking glucocorticoids PRN, prednisone ≥1mg/day in average.)
- •Patients expected to be on glucocorticoid treatment for 3 months after entry.
- •Patients with an osteopenic mean lumbar spine (LS; L1-L4) or femoral neck bone mineral density (BMD; -1 < T-score < -2.5)
- •Patients who provide a written consent of participating in this study.
Exclusion Criteria
- •Patients with condition that may interfere with the evaluation of spinal or hip osteoporosis by DXA such as two or more vertebral (L1-L4) fractures or other vertebral deformity
- •Patients with hypercoagulability risk factors or a history of deep vein thrombosis and pulmonary embolism
- •History of allergic reactions or intolerance to bazedoxifene or other SERM
- •Patients receiving bisphosphonates, parathyroid hormone, SERMs, or anticonvulsants therapies within 6 months prior to entry
- •Patients with known bone disorders such as osteomalacia, renal osteodystrophy and hyperparathyroidism
- •Patients with undiagnosed uterine bleeding
- •Patients with severe renal impairment or creatinine clearance <30ml/min
Arms & Interventions
Bazedoxifene & Calcium/Vit D
Active Comparator
- Enrollment: 57
- Drug: Bazedoxifene 20 mg/day (Viviant)
- Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)
Intervention: Bazedoxifene (Drug)
Bazedoxifene & Calcium/Vit D
Active Comparator
- Enrollment: 57
- Drug: Bazedoxifene 20 mg/day (Viviant)
- Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)
Intervention: Calcium/Vit D (Drug)
Calcium/Vit D
Active Comparator
- Enrollment: 57
- Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)
Intervention: Calcium/Vit D (Drug)
Outcomes
Primary Outcomes
Change of Bone Mineral Density (BMD)
Time Frame: Baseline and 48 weeks
BMD of the L-spine (L1-4) and femur neck was assessed by dual-energy x-ray absorptiometry (DXA) (Hologic®, Discovery W, Hologic APEX software version 2.3.1; Bedford, MA, USA). BMD in the L-spine was estimated as the mean of individual measurements for L1-L4 excluding any fractured or otherwise deformed vertebrae. The technician who was responsible for measuring BMD was blinded to the details of the study.
Secondary Outcomes
- Change of Trabecular Bone Score (TBS)(Baseline and 48 weeks)
- Change in serum osteocalcin(Baseline, 24 weeks and 48 weeks)
- Development of the thoracic and lumbar vertebrae for deformities by visual inspection(Baseline and 48 weeks)
- Development of any fractures including nonvertebral fractures(Baseline, 24 weeks and 48 weeks)
- Change in serum C-terminal telopeptide (CTX)(Baseline, 24 weeks and 48 weeks)
- Change in urine N-telopeptide (NTX)(Baseline, 24 weeks and 48 weeks)
- Change in serum bone specific alkaline phosphatase(Baseline, 24 weeks and 48 weeks)
Investigators
Yoon-Kyoung Sung
Associate professor
Hanyang University
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 4
Effect of Bazedoxifene to osteoporotic patients under active vitamin D treatmentosteoporosisJPRN-UMIN000007398Gerontology Osaka City University50
Completed
Phase 3
Effects of Arzoxifene on Bone Fractures and Incidence of Breast CancerOsteoporosis, PostmenopausalNCT00088010Eli Lilly and Company9,369
Completed
Phase 4
Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid TherapyOsteoporosisNCT00371956Tuen Mun Hospital114
Completed
Phase 3
Effects of Arzoxifene on Bone Mass and the UterusPostmenopausal Bone LossNCT00085956Eli Lilly and Company300
Completed
Phase 3
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal WomenOsteoporosisNCT00205777Pfizer7,609